سعر ستاتيوريك 120مجم 30 قرص 2024

Staturic 120 mg (Mash Premiere, Egypt), 30 film-coated tablets: febuxostat 120 mg, a xanthine oxidase inhibitor used to lower serum uric acid in gout.

• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including history or presence of tophus and/or gouty arthritis), in adultsPopulation: AdultsEuropean Medicines Agency (EMA)
• Prevention and treatment of hyperuricaemia in adults undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumour lysis syndrome (120 mg once daily, started 2 days before cytotoxic therapy, for at least 7 days)Population: AdultsEuropean Medicines Agency (EMA)

• Hypersensitivity to the active substance or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)

• In patients with pre-existing major cardiovascular disease (e.g. myocardial infarction, stroke, unstable angina) more fatal cardiovascular events were seen with febuxostat than allopurinol in development and in the CARES study, although the later FAST study showed non-inferiority; treatment of such patients should be cautious.International label, same formulation · European Medicines Agency (EMA)

• Azathioprine / mercaptopurineNot recommended: xanthine oxidase inhibition may increase mercaptopurine/azathioprine plasma concentrations causing severe toxicity. Where unavoidable, reduce the mercaptopurine/azathioprine dose to 20% or less of the previous dose and monitor closely.European Medicines Agency (EMA)

• Data on a very limited number of exposed pregnancies have not shown adverse effects; potential human risk is unknown and febuxostat should not be used during pregnancy.General active-ingredient information · European Medicines Agency (EMA)
• Unknown whether excreted in human milk; animal studies showed excretion in milk and impaired development of suckling pups; a risk to the suckling infant cannot be excluded and it should not be used while breastfeeding.General active-ingredient information · European Medicines Agency (EMA)

• Febuxostat: 2-arylthiazole derivative that lowers serum uric acid by potent, selective, non-purine inhibition of xanthine oxidase (oxidised and reduced forms), which catalyses hypoxanthine to xanthine to uric acid (EU SmPC).